Bienvenido a Med Info Alert, el servicio de literatura científica de Boehringer Ingelheim que te permite estar al día de las publicaciones más recientes y relevantes sobre la enfermedad pulmonar intersticial difusa (EPID).
Si estás interesado en recibir alguna publicación de este mes, a continuación, puedes descargarla o acceder a tu cuenta para solicitarla.
¿También quieres estar actualizado los próximos meses con las publicaciones más recientes sobre EPID? Regístrate en avances en fibrosis pulmonar.
Zhu J, Zhou D, Wang J, Yang Y, Chen D, He F, Li Y. A Causal Atlas on Comorbidities in Idiopathic Pulmonary Fibrosis: A Bidirectional Mendelian Randomization Study. Chest. 2023
Kreuter M, Bendstrup E, Jouneau S, Maher TM, Inoue Y, Miede C, Lievens D, et al. Weight loss and outcomes in subjects with progressive pulmonary fibrosis: data from the INBUILD trial. Respir Res. 2023
Stanel SC, Rivera-Ortega P. Present and future perspectives in early diagnosis and monitoring for progressive fibrosing interstitial lung diseases. Front Med (Lausanne). 2023
Platenburg MGJP, van der Vis JJ, Grutters JC, van Moorsel CHM. Decreased Survival and Lung Function in Progressive Pulmonary Fibrosis. Medicina (Kaunas). 2023
Suzuki A, Kamio K, Takeno M, Terasaki Y, Taniuchi N, Sato J, Nishijima N, et al. Pulmonary sarcoidosis complicated by rheumatoid arthritis in a patient presenting with progressive fibrosing interstitial lung disease and treated with nintedanib: a case report and literature review. Ther Adv Respir Dis. 2023
Wang L, Zhu M, Li Y, Yan P, Li Z, Chen X, Yang J, et al. Serum proteomics identify biomarkers associated with the pathogenesis of idiopathic pulmonary fibrosis. Mol Cell Proteomics. 2023
Sobiecka M, Szturmowicz M, Lewandowska KB, Barańska I, Zimna K, Łyżwa E, Dybowska M, et al. Bronchoalveolar Lavage Cell Count and Lymphocytosis Are the Important Discriminators between Fibrotic Hypersensitivity Pneumonitis and Idiopathic Pulmonary Fibrosis. Diagnostics (Basel). 2023
Jee AS, Stewart I, Youssef P, Adelstein S, Lai D, Hua S, Stevens W, et al; Australian Scleroderma Cohort Study, Australian Scleroderma Interest Group, Australian Idiopathic Pulmonary Fibrosis Registry, and associated investigators. A composite serum biomarker index for the diagnosis of systemic sclerosis interstitial lung disease: a multicentre, observational, cohort study. Arthritis Rheumatol. 2023
Adegunsoye A, Newton CA, Oldham JM, Ley B, Lee CT, Linderholm AL, Chung JH, et al. Telomere length associates with chronological age and mortality across racially diverse pulmonary fibrosis cohorts. Nat Commun. 2023
Watase M, Mochimaru T, Kawase H, Shinohara H, Sagawa S, Ikeda T, Yagi S, et al. Diagnostic and prognostic biomarkers for progressive fibrosing interstitial lung disease. PLoS One. 2023
Kolb M, Crestani B, Maher TM. Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis. Eur Respir Rev. 2023
Podolanczuk AJ, Cottin V. A Narrative Review of Real-World Data on the Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis. Adv Ther. 2023
PC-ES-110536